Compare Lufax Holding Ltd (LU) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lufax Holding Ltd vs GeneDx Holdings Corp — how do they compare? Lufax Holding Ltd trades at $0.98 (market cap $982.89M), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 2.1× Lufax Holding Ltd's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lufax Holding Ltd for 13 Days and GeneDx Holdings Corp for 19 Days on average.
| LU | WGS | |
|---|---|---|
Market Cap | $982.89M | $2.02B |
Volume | 3,323,384 | 734,640 |
Sector | Financials | Health |
52-Week High | $3.93 | $167.51 |
52-Week Low | $0.95 | $34.51 |
Typical Hold Time | 13 Days | 19 Days |
Enterprise Value | $58.81B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LU trades at $0.98, down 0.11% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of $2.10 billion on $23.11 billion revenue in 2025, with negative profit margins and ROE. Recent corporate actions include a 10:1 reverse stock split effective October 23, 2026. Analyst consensus remains positive with 69% buy ratings, though earnings have consistently missed expectations.
LU presents a deep value opportunity with P/S of 0.25 and P/B of 0.07, but faces significant execution risks amid declining revenue and persistent losses. The company's strong parent backing from Ping An and improving operational cash flow provide some stability, but regulatory headwinds in China's consumer lending market remain a concern for sustained recovery.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
